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LETTER TO THE EDITOR Open Access
Chemerin is elevated in multiple myeloma
patients and is expressed by stromal cells
and pre-adipocytes
Marita Westhrin1,2* , Siv Helen Moen1,2, Ida Bruun Kristensen3, Glenn Buene1,2, Anne Kærsgaard Mylin4,
Ingemar Turesson5, Niels Abildgaard3, Anders Waage1,6 and Therese Standal1,2,6
Abstract
Chemerin is a recently discovered adipokine shown to be involved in both inflammatory and metabolic processes.
Here, we demonstrate that chemerin serum levels are elevated in patients with multiple myeloma and that it
increases with disease progression. We found that chemerin is expressed by stromal cells and preadipocytes,
whereas its receptor CCRL2 is expressed by primary myeloma cells, suggesting a paracrine signaling loop between
bone marrow stromal cells/adipocytes and myeloma cells. This is the first study exploring chemerin and its
receptors in multiple myeloma.
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To the editor,
Multiple myeloma is a hematological malignancy
caused by clonal proliferation of malignant plasma
cells in the bone marrow. Although novel therapies
have increased survival of multiple myeloma patients,
it remains an incurable disease. Myeloma cells de-
pend on the microenvironment for adhesion, survival
and drug resistance. Targeting the microenvironment
is vital for novel therapy strategies [1].
Bone marrow adipocytes have emerged as import-
ant players in cancer development [2]. They serve as
energy reservoirs, secrete fatty acids and adipokines
and take part in regulating bone homeostasis. Since
myeloma is a disease of the elderly, and adiposity in-
creases with age, the role of adipocytes in myeloma
are currently gaining interest. Adiposity has already
been shown to increase the risk of myeloma in
several studies [3, 4]. Further, it has been shown that
adipocytes may affect proliferation, apoptosis and
migration of myeloma cells as well as protecting
them during chemotherapy [5, 6].
Chemerin (also known as TIG2 and RARRES2) was
initially identified as an adipokine involved in adipo-
genesis and adipocyte metabolism [7]. Chemerin is a
modulator of inflammation and it has been suggested
as a tumor marker in several cancers [8].
Due to the emerging important role of adipocytes in
myeloma, and the role of chemerin in cancers in par-
ticular, we measured chemerin serum levels in patients
and age— and gender matched healthy volunteers. The
patient serum samples were collected at diagnosis during
a randomized phase 3 clinical trial, which compared the
effect of two different doses of pamidronate on bone in
the years 2001–2005 [9]. Out of the original 504 pa-
tients, serum samples were available for 122 patients
(patient characteristics, Table 1). We found a significant
difference between chemerin concentration in patients
(mean = 199.2 ng/ml ± 88.2, n = 122) and healthy con-
trols (mean = 156.5 ng/ml ± 52.5, n = 58) (p < 0.001,
Mann-Whitney) as shown in Fig. 1a. Chemerin
serum levels were significantly higher in patients in
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ISS stage III (mean = 255.2, ± 106.5, n = 28) com-
pared to patients in ISS stage I (mean = 168.2, ±
65.4, n = 33) (p < 0.001), and patients in stage II
(mean = 189.5, ± 75.8, n = 47) (p < 0.05, Kruskal
Wallis with Dunns post hoc test) as shown in Fig. 1b. As
chemerin levels correlated with disease stage we compared
overall survival in patients with above (> 192.1 ng/ml)
and below median (≤ 192.1) serum chemerin levels.
Overall survival did not differ significantly between
the two groups (median survival 61.9 months (n = 61)
for the low chemerin group versus median survival
47.8 months (n = 61) for the high chemerin group,
p = 0.318 (Mantel-Cox Test). In this patient cohort,
chemerin correlated with CRP (spearman r = 0.191
p < 0.05) and serum β-microglobulin (spearman r = 0.332,
p < 0.001), but not with number of plasma cells (%), the
M-component (g/dl), body mass index, s-LDH (ukat/
L) or s-calcium (mmol/L). Chemerin serum levels did
not associate with bone disease status, or time to
SRE. To compare levels of chemerin in the blood
and the bone marrow, we analyzed matching blood
and bone marrow- plasma samples from 10 myeloma
patients (8 from time of diagnosis and 2 from re-
lapse) available at Biobank1®. Chemerin blood plasma
levels correlate strongly with chemerin bone marrow
plasma levels (spearman r = 0.894, p < 0.005) as
shown in Fig. 1c. There was a tendency to increased
amounts of chemerin in the bone marrow plasma
compared with levels in blood plasma ((mean =
251.3 ng/ml vs 214.7 ng/ml), n = 10).
To examine which cells may be producers of che-
merin in the bone marrow we examined gene expres-
sion by qPCR in stromal cells isolated from myeloma
patients (n = 15), primary myeloma cells (n = 24) and
myeloma cell lines (n = 9). We found that chemerin
was significantly higher expressed in stromal cells
compared with primary myeloma cells, and that mye-
loma cell lines expressed lower levels than primary
myeloma cells, Fig. 1d. Since chemerin was initially
identified as an adipokine we further measured che-
merin protein levels in the supernatants from bone
marrow-derived mesenchymal stromal cells (n = 3)
differentiated towards adipocytes using the hMSC
Adipogenic Differentiation BulletKit™ Medium (Lonza).
Interestingly, pre-adipocytes produce and secrete che-
merin at high levels, as shown in Fig. 1e. The in-
crease in chemerin protein levels corresponded with
an increase in chemerin mRNA levels (not shown).
Chemerin mediates effect through its receptors
CMKLR1 and GPR1, but it can also bind to CCRL2,
which is a non-signaling receptor [10]. To examine re-
ceptor expression for chemerin in primary myeloma
cells, we utilized the CoMMpass data series, which con-
tains RNA-sequencing data from 673 newly diagnosed
myeloma patients. We found that CCRL2 mRNA was
expressed in most of the patients while CMKLR1 mRNA
was expressed in a fraction of the patients. In line with
qPCR results in Fig. 1c chemerin (RARRES2) was not
expressed by primary myeloma cells, Fig. 1f. Interest-
ingly, primary myeloma cells expressed more CCRL2
and CMKLR1 mRNA compared with multiple mye-
loma cell lines (Additional file 1: Figure S1).
In conclusion, chemerin levels in serum are elevated
in patients with multiple myeloma compared to
healthy controls. Chemerin serum levels correlate
with disease stage. Stromal cells obtained from mye-
loma patients and pre-adipocytes produce chemerin,
whereas the receptors CCRL2 and CMKLR1 are
expressed by myeloma cells. Thus, we propose that
chemerin may mediate a paracrine signaling loop be-
tween stromal cells/adipocytes and myeloma cells.
Additional file
Additional file 1: Figure S1. Expression of CCRL2 and CMKLR1 in
primary myeloma cells (pMM, n = 24) and cell lines (n = 9) analyzed by
qPCR. GAPDH was used as an endogenous control. (DOCX 51 kb)
Abbreviations
CCRL2: C-C chemokine receptor-like 2; CMKLR1: Chemerin Chemokine-Like
Receptor 1; GPR1: G Protein-Coupled Receptor 1; hMSC: Human
mesenchymal stromal cell; ISS: International staging system;
RARRES2: Retinoic Acid Receptor Responder 2; SRE: Skeletal related event
Table 1 Patient characteristics
Patients (n = 122) Controls (n = 58)
Age (years) 62 (37–86) 62 (43–81)
Sex (female) 60 (49%) 31 (53%)
ISS stage
I 33 (27%)
II 47 (39%)
III 28 (23%)
Unknown 14 (11%)
M-component
IgG 75 (61%)
IgA 29 (24%)
Light chain 6 (5%)
Unknown 12 (10%)
Skeletal affection
None 12 (10%)
Limited 49 (40%)
Osteoporosis 9 (7%)
Advanced 48 (39%)
Unknown 4 (3%)
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Fig. 1 a Serum levels of chemerin measured by ELISA (R&D Duoset) in 122 patients, and 58 healthy age and gender-matched controls. b Chemerin
levels based on ISS stage. c Blood- and bone marrow plasma levels of chemerin in myeloma patients obtained from our biobank (n = 10). d PCR
analysis of chemerin (RARRES2) expression by myeloma-derived stromal cells (n = 15), primary myeloma cells (n = 24) and myeloma cell lines (n = 9).
e Healthy bone marrow-derived mesenchymal stromal cell donors differentiated towards adipocytes (n = 3 donors) according to the manufacturer’s
instructions. Conditioned cell culture media were harvested at every medium change. Chemerin levels in the conditioned media were measured by
ELISA (R&D Duoset). Error bars = SEM f Expression of chemerin (RARRES2), CCRL2 and CMKLR1 in malignant plasma cells from 673 myeloma patients
available in the CoMMpass database, release IA9. Red bars indicate mean in a, b, d and f
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